Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sage Therapeutics Inc | SAGE | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 13.28 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 13.28 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 10.92 - 59.99 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 13.28 | USD |
Sage Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 798.22M | 60.11M | - | 86.46M | -541.49M | -9.01 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Sage Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAGE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 13.74 | 14.97 | 13.19 | 13.66 | 1,202,706 | -0.46 | -3.35% |
| 1 Month | 17.05 | 17.505 | 10.92 | 14.17 | 1,291,765 | -3.77 | -22.11% |
| 3 Months | 23.94 | 27.39 | 10.92 | 18.57 | 1,085,088 | -10.66 | -44.53% |
| 6 Months | 19.86 | 28.26 | 10.92 | 20.38 | 974,373 | -6.58 | -33.13% |
| 1 Year | 48.50 | 59.99 | 10.92 | 25.10 | 1,109,544 | -35.22 | -72.62% |
| 3 Years | 79.29 | 80.23 | 10.92 | 34.31 | 775,509 | -66.01 | -83.25% |
| 5 Years | 162.01 | 193.56 | 10.92 | 49.42 | 756,166 | -148.73 | -91.80% |
Sage Therapeutics Description
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |
